Clinical trials
Leukemia, Myeloid clinical trials
Below are recruiting leukemia, myeloid clinical trials, each written for real people, not researchers. We’re tracking 597 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07478991RecruitingPhase 3
Azacitidine and venetoclax with or without quizartinib for older or unfit AML patients
This trial tests if adding quizartinib to the standard combination of azacitidine and venetoclax improves outcomes for older adults or those with health conditions who cannot have intensive chemotherapy for acute myeloid leukemia (AML). It may help patients with certain genetic changes in the FLT3 or NPM1 genes.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Gilbert, ArizonaAges 18 years+ - NCT06580106Recruiting
Genes, side effects, and response to azacitidine and venetoclax in AML
This study looks at how genes affect the response to a combination of two drugs (azacitidine and venetoclax) in people with AML. It aims to understand why some people have side effects and how well the treatment works.
Charlotte, North CarolinaAges 18 years+ - NCT07392970RecruitingPhase 2
Motixafortide to improve AML treatment response after chemo
This trial tests if adding motixafortide can help find and eliminate leftover leukemia cells in people with AML who are in remission after initial chemotherapy. The goal is to make remission deeper and more durable.
St Louis, MissouriAges 18 years+ - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07712848RecruitingPhase 3
Comparing 3 drug combos for newly diagnosed AML
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
Kunming, YunnanAges 18–65 - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT05429632RecruitingPhase 3
Mocravimod to prevent relapse after bone marrow transplant for AML
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
Birmingham, AlabamaAges 18–75 - NCT03326310RecruitingPhase 1
Selumetinib plus azacitidine for high-risk blood cancers
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Chicago, IllinoisAges 18 years+ - NCT03459534RecruitingPhase 3
Radotinib for CML patients after prior TKI failure
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
BarnaulAges 18 years+ - NCT03728335RecruitingPhase 2
Enasidenib maintenance after transplant for IDH2-mutated AML
This trial studies enasidenib to help keep acute myeloid leukemia (AML) under control after an allogeneic stem cell transplant in people with an IDH2 mutation. It may help reduce the chance of the leukemia coming back by targeting the mutation that drives the disease.
Duarte, CaliforniaAges 18 years+ - NCT03828773Recruiting
Azole antifungal prevention for leukemia during low white blood counts
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Ghent, BelgiumAges 18 years+ - NCT04010877RecruitingPhase 1/Phase 2
CAR-T therapy for AML targeting leukemia markers
This early-phase trial tests a personalized immune treatment (CAR-T cells) that targets certain markers found on AML (acute myeloid leukemia) cells. It aims to see if the treatment can help people whose leukemia has specific marker patterns.
Shenzhen, GuangdongAges 6 months–75 years - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04168502RecruitingPhase 3
Gemtuzumab added to chemotherapy for certain adult AML
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
AlessandriaAges 18–60 - NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Birmingham, AlabamaAges Up to 21 years - NCT04628026RecruitingPhase 3
Venetoclax plus chemotherapy for new AML or high-risk MDS
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
InnsbruckAges 18–75 - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT04769947Recruiting
Registry for CML patients in deep remission after stopping pills
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
TurinAges 18 years+ - NCT04869683Recruiting
Collecting blood and tissue samples in myelodysplastic syndrome
This trial collects and stores biological samples (like blood or other lab materials) from people with myelodysplastic syndrome, to help researchers learn more about the disease. It may help future diagnosis or treatments, even if it doesn’t directly test a new medicine.
BrestAges 18 years+ - NCT04953897RecruitingPhase 1
Oral decitabine for cancer patients with kidney problems
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Houston, TexasAges 18 years+
Hear when a new Leukemia, Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, myeloid?
- Yes. Clin2 currently lists 597 recruiting leukemia, myeloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, myeloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, myeloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.